WithdrawnPhase 2NCT04776876

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

Studying Carcinoid syndrome

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: M.D. Anderson Cancer Center
Principal Investigator: Daniel M Halperin, MD
M.D. Anderson Cancer Center
Intervention: Retifanlimab(biological)
Eligibility: 18 years · All sexes
Timeline: 2021 – 2021

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04776876 on ClinicalTrials.gov

Other trials for Carcinoid syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT07087054
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Crinetics Pharmaceuticals Inc.
RECRUITINGNCT05756608
Fibrosis in Chronic and Delayed Myocardial Infarction
University of Edinburgh
ACTIVE NOT RECRUITINGNANCT05064514
Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
Queen Mary University of London
ACTIVE NOT RECRUITINGEARLY PHASE1NCT04993261
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
M.D. Anderson Cancer Center

See all trials for Carcinoid syndrome →

← Back to all trials